<DOC>
	<DOCNO>NCT00003590</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy hydroxyurea use different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well hydroxyurea work treat patient unresectable benign meningioma .</brief_summary>
	<brief_title>S9811 Hydroxyurea Treating Patients With Unresectable Benign Meningioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine partial complete response rate patient unresectable benign meningioma treat hydroxyurea . - Assess quantitative qualitative toxic effect drug patient population . OUTLINE : Patients receive oral hydroxyurea twice daily 2 year absence disease progression unacceptable toxicity . Patients follow 3 month , 6 month , every 6 month 3 year . PROJECTED ACCRUAL : A total 38 patient accrue study within 13 month .</detailed_description>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable primary , recurrent , residual benign meningioma Measurable disease CT scan MRI Must disease progression within past 10 year OR progressive neurologic deficit within past 6 month Must undergone prior radiotherapy subsequent disease progression OR refuse radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least low limit normal Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception No malignancy within past 5 year except adequately treat basal squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy meningioma Prior mifepristone allow No concurrent chemotherapy Endocrine therapy : Concurrent glucocorticoid hormone replacement therapy allow stable dose maintain least 72 hour prior CT scan MRI No concurrent antitumor hormonal therapy Radiotherapy : See Disease Characteristics At least 6 month since prior radiotherapy No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult grade I meningioma</keyword>
</DOC>